A bone implant for enclosing bone material is provided. The bone implant comprises a nonwoven mesh having an inner surface and an outer surface opposing the inner surface and configured to receive a bone material when the inner surface of the mesh is in an open configuration. A plurality of projections are disposed on or in at least a portion of the inner surface of the mesh, the outer surface of the mesh or both the inner and outer surfaces of the mesh, the plurality of projections extending from at least the portion of the inner surface, the outer surface of the mesh or both the inner and outer surfaces of the mesh and are configured to engage a section of the inner surface of the mesh or a section of the outer surface of the mesh or both in a closed configuration so as to enclose the bone material.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

A method of forming an immunomodulatory implant operatively arranged to chemotactically facilitate bone morphogenesis, the method including forming a matrix of a first material, the matrix including an outer surface, and a plurality of pores, and applying an antigen to the matrix, wherein the antigen including at least one of a bacterial antigen or a viral antigen.

The present invention provides a porous tricalcium phosphate material, modified from a coral bone and having a plurality of pores, wherein the average compressive strength of the porous tricalcium phosphate material is 4 kgf to 9 kgf. Besides, the present invention also provides a method for bone healing and a manufacturing method for the porous tricalcium phosphate material. The porous tricalcium phosphate material of the present invention has the advantages of biocompatibility and no immunological rejection response, and also has significantly better mechanical properties and bone healing efficacy so as to better meet the needs of the patients.

The present invention provides a porous tricalcium phosphate material, modified from a coral bone and having a plurality of pores, wherein the average compressive strength of the porous tricalcium phosphate material is 4 kgf to 9 kgf. Besides, the present invention also provides a method for bone healing and a manufacturing method for the porous tricalcium phosphate material. The porous tricalcium phosphate material of the present invention has the advantages of biocompatibility and no immunological rejection response, and also has significantly better mechanical properties and bone healing efficacy so as to better meet the needs of the patients.

A method of coating a bone material in a container is provided. The method comprising adding the bone material to an opening of the container and sealing the opening of the container so that the bone material is disposed within an interior of the container; adding a liquid coating material to the interior of the container through an inlet of the container so as to coat at least a portion of the bone material with the liquid coating material; removing any excess coating material from the container from the interior through an outlet of the container; and removing the coated bone material from the container. A system of coating bone material under a sterilized environment is also provided.

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 μg per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 μm. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.

An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof in a range of from 2 to 1000 μg per ml of autologous blood; and hydroxyapatite, tri-calcium phosphate, or a mixture thereof as a compression resistant matrix, the compression resistant matrix being provided in the form of particles having a particle size in a range of from above 74 to 8000 μm. Preferably, a ratio between the compression resistant matrix and the autologous blood coagulum is from 50 to 500 mg of the compression resistant matrix per mL of the autologous blood coagulum.

A biomaterial including a porous biocompatible structure having interconnected pores, wherein the pores have interior walls and are interconnected by passageways, the interior walls and passageways being coated with an osteoinductive aqueous demineralized bone extract solution, the aqueous demineralized bone extract solution including growth factors, proteins, a demineralized bone matrix and at least one of a weak acid and a guanidine hydrochloride, wherein the demineralized bone matrix is present per 100 g of the solution in an amount of from about 2 g to about 10 g.

A biomaterial including a porous biocompatible structure having interconnected pores, wherein the pores have interior walls and are interconnected by passageways, the interior walls and passageways being coated with an osteoinductive aqueous demineralized bone extract solution, the aqueous demineralized bone extract solution including growth factors, proteins, a demineralized bone matrix and at least one of a weak acid and a guanidine hydrochloride, wherein the demineralized bone matrix is present per 100 g of the solution in an amount of from about 2 g to about 10 g.